启明星 | 和誉医药宣布与默克就Pimicotinib（ABSK021）达成独家许可协议 | Bilingual

日前，启明创投投资企业和誉医药（02256.HK）宣布，已与领先的科技公司默克公司（下称“默克”）就其自主研发的CSF-1R小分子抑制剂Pimicotinib（ABSK021）达成独家许可协议。 

根据协议条款，默克将获得在中国内地、中国台湾、中国香港和中国澳门针对Pimicotinib就所有适应症进行商业化的许可，和誉医药将保留在授权区域内独家开发Pimicotinib的权利。此外，默克可以在达到行权条件并支付额外对价后行使选择权，以获得Pimicotinib在全球范围内的商业化权利，以及在特定条件下，联合开发Pimicotinib其它适应症的权利。

根据协议条款，和誉医药将获得7000万美元的一次性、不可退还的首付款，如果默克行使全球商业化选择权，和誉医药还将获得额外的行权费；加上研发里程碑付款及销售里程碑付款，以上潜在的付款总额可能高达6.055亿美元，除此之外默克还将向和誉医药支付高至两位数百分比的销售提成。

和誉医药创始人兼首席执行官徐耀昌博士表示：“和誉医药此次与默克的合作是推动Pimicotinib在全球范围内商业化进程的重要里程碑，为今后公司管线的商业化路径提供了新的模式。我们很高兴与领先的跨国药企默克合作，共同加速Pimicotinib的全球审批以及商业化步伐，力求早日为患者带来新的治疗选择。”

“通过与和誉医药的合作，我们有机会为中国严重缺乏治疗选择的患者群体提供同类首创的治疗方案，并可能惠及更多国家和地区的患者。”默克医药健康业务全球首席市场官Andrew Paterson表示，“Pimicotinib提供了解决重大未被满足医疗需求的机会，并让默克在中国这一全球第二大医药市场扩大肿瘤治疗的商业足迹。”

Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck

Qiming Venture Partners' portfolio company Abbisko Therapeutics (SEHK:2256) announced that it has entered into a licensing agreement with Merck, a leading science and technology company. 

Under the terms of the agreement, Merck will be granted an exclusive license to commercialize products comprising or containing pimicotinib (ABSK021) for all indications in Chinese mainland, Hong Kong, Macau and Taiwan (the "Licensed Territory"), and Abbisko Therapeutics will retain the exclusive rights to develop pimicotinib within the Licensed Territory. Abbisko Therapeutics has also granted Merck an exclusive option for global commercial rights of pimicotinib, subject to the terms and conditions as agreed between the parties (the "Global Commercialization Option"). In addition, Merck has the option to co-develop pimicotinib in additional indications under certain conditions.

Pursuant to the License Agreement, Abbisko Therapeutics will receive a one-time, non-refundable down payment of US$ 70 million. In the event that Merck exercises the Global Commercialization Option, Merck will pay Abbisko Therapeutics an additional option exercise fee. The aggregate amount of upfront payment, exercising payment, and development and commercialization milestone adds up to US$ 605.5 million, plus a double-digit percentage (%) royalty on actual annual net sales.

Dr. Xu Yao-chang, Chairman of Abbisko Therapeutics, said that "The collaboration with Merck is an important milestone in advancing the global commercialization process of pimicotinib, and provides a new model for the commercialization path of the company's pipeline in the future. We are pleased to collaborate with a leading multinational pharmaceutical company, jointly accelerating the global approval and commercialization pace of pimicotinib, and striving to bring new treatment options to patients as soon as possible."

"We have the opportunity through our partnership with Abbisko to deliver a first-in-class treatment for a critically underserved patient population in China and potentially beyond," said Andrew Paterson, Chief Marketing Officer for the Healthcare business sector of Merck. "Pimicotinib provides an opportunity to address a significant unmet medical need and for us to expand our commercial footprint in oncology in China, the second largest pharmaceutical market in the world."